Industry News

Rosetta Genomics Ltd., a leading developer and provider of microRNA-based and other molecular diagnostics, today announces the results from an analytical validation study confirming that the Company’ s first-of-its-kind microRNA classifier for indeterminate thyroid nodules, RosettaGX Reveal™, can now be used with liquid-based cytology samples. The data will be presented in a poster at the upcoming 86 th Annual Meeting of the American Thyroid..."/>
Data Validating the Utility of RosettaGX Reveal™ with Liquid-based Cytology Samples will be Presented at the 86th Annual Meeting of the American Thyroid Association
Brainsway Ltd., the leader in the development of advanced noninvasive treatments for brain disorders, announced that it has received local regulatory approval for the marketing and distribution of Brainsway Deep TMS in Mexico. The company entered an exclusive distribution and marketing agreement with Moksha8, a leading specialty pharmaceutical company in Latin America, who has exclusive rights to distribute Deep TMS in Mexico.."/>
Brainsway Attains Regulatory Approval for Marketing Deep TMS in Mexico
Amedisys, Inc., as Senior Vice President and Chief Clinical Officer.. In her new role, Sender will oversee clinical practice and quality, set and maintain clinical operations standards and develop and implement clinical programs and clinical education. She will also be responsible for every aspect of patient care and quality outcomes and support clinicians across the organization."/>
Amedisys Welcomes Susan Sender as New Chief Clinical Officer
Intu Properties dropped 2.1 pc, or 6.2 p, to 289.2 p."/>
Daily Mail, London, market report column [Daily Mail, London]
MyoKardia, Inc., a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, will host a Research and Development Day for analysts and investors on Sept. 21, 2016, at 8:30 a.m. ET in New York City.. During the R&D day, presentations by members of MyoKardia’ s management team and guest speakers will include:. MyoKardia Vision 2020 Tassos Gianakakos, Chief..."/>
MyoKardia to Host R&D Day on September 21
Aeterna Zentaris Inc. today announced that the remaining 8,064 Series B Common Share Purchase Warrants issued in connection with the Company’ s March 2015 financing expired on September 12, 2016 without being exercised. The Company had 9,939,863 Common Shares issued and outstanding as of the close of business on September 13, 2016.. David A. Dodd, President and Chief Executive Officer of the Company, explained,“ All Series B Warrants issued in connection with..."/>
Aeterna Zentaris Announces Expiration of Remaining Series B Warrants
Rennova Health, Inc.,, a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers, announced today that on September 13, 2016, Nasdaq confirmed that the Company had been granted an extension of 180 days to comply with rule 5550, relating to the bid price of the Company’ s common stock not meeting the minimum $1.00 per share requirement for continued listing. Nasdaq staff determined that..."/>
Rennova Health, Inc. Granted 180 Day Extension by Nasdaq
WellCare Health Plans, Inc., awarded micro-grants to 10 nonprofit community-based organizations in Kentucky..."/>
WellCare Gives Micro-Grants to Community-Based Organizations that Provide Transportation Assistance Services in Kentucky
Flexion Therapeutics, Inc. announced today the appointment of Mark Stejbach, Senior Vice President and Chief Commercial Officer at Alkermes plc, to its Board of Directors as the company prepares for commercialization of its drug candidate Zilretta™, a potential treatment for patients with moderate to severe knee osteoarthritis pain. Flexion plans to submit a new drug application in the fourth quarter of 2016 to the U.S. Michael Clayman, MD,..."/>
Flexion Therapeutics Announces Appointment of Mark Stejbach to its Board of Directors
Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, among other core businesses, announced today that Big Screen surgery with 4 K UHD endoscopy is now available for ear, nose and throat surgeons through the Olympus VISERA 4 K UHD System. VISERA 4 K UHD, the first of many products from the Sony Olympus Medical Solutions joint-venture, is a state-of-the-art Big Screen..."/>
Olympus Launches VISERA 4K UHD System for Improving Visualization up to 4x During ENT Procedures
Propanc Health Group Corporation, an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that the September 8 presentation from..."/>
Propanc Health Group Corporation Presentation Now Available for On-Demand Viewing
PhaseRx, Inc., a biopharmaceutical company developing mRNA products to correct life-threatening inherited liver diseases in children, today announced that the company will be presenting at the 2016 Aegis Growth Conference. Robert W. Overell, Ph.D., president and chief executive officer, will provide an overview of the company and its development stage programs on Wednesday, September 21, 2016 at 3:30 p.m. PDT. The investor conference will be..."/>
PhaseRx to Present at the 2016 Aegis Growth Conference
Delcath Systems, Inc., an interventional oncology Company focused on developing safe and effective treatments for primary and metastatic liver cancers, announces that results from two single-institution studies conducted in Germany of use of the Delcath Hepatic CHEMOSAT ® Delivery System to treat patients with liver metastases were..."/>
Data Supporting CHEMOSAT Presented at the Cardiovascular and Interventional Radiology Society of Europe Conference
Relmada Therapeutics, Inc., a clinical-stage company developing novel therapies for the treatment of central nervous system diseases, today announced that it has filed a motion to amend its amended complaint against Laidlaw& Company Ltd. in the U.S. District Court for the District of Nevada. The motion to file a second amended complaint is part of the lawsuit that the Company had previously filed in the Nevada District Court."/>
Relmada Therapeutics Files Amended Complaint Against Laidlaw and Its Principals, Matthew Eitner and James Ahern
Varian Medical Systems, today announced it has been selected by Proton Therapy Pte., Ltd. to install and service a Varian ProBeam ® Compact single-room proton therapy system for a new oncology center in Singapore. Construction of the new center is expected to begin by the end of 2016. In addition to a 10 year service agreement, Varian will also provide its Eclipse™ treatment planning system training environment for use by Proton Therapy Pte.,..."/>
Varian Selected to Provide Compact Single-room Proton Therapy System for New Oncology Center in Singapore
Aytu BioScience Inc., a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that it will present at two upcoming investor conferences in September 2016.. Aytu management will provide an overview of the company's business during live presentations, and will be available to participate in one-on-one meetings with investors who are registered to attend the..."/>
Aytu BioScience to Present at Two Upcoming Investor Conferences
Abbott Laboratories is among 13 Chicago-area companies on the list released Wednesday by the Dave Thomas Foundation, a nonprofit created by the late Wendy's founder Dave Thomas-- himself adopted-- to help find homes for foster kids."/>
Which Chicago-area companies offer the best adoption benefits? [Chicago Tribune]
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced the launch of a new website for its expanded access program and its planned participation at the 63 rd American Association of Neuromuscular& Electrodiagnostic Medicine conference which will be held on September 14-17, 2016 at the Hilton New Orleans..."/>
Catalyst Pharmaceuticals Announces Launch of Expanded Access Program Website and Participation at the American Association of Neuromuscular & Electrodiagnostic Medicine Conference
Medovex Corp., a developer of medical technology products, today announced that the Company has entered into an international distribution agreement with M.Fast Technologies LTD, a supplier of innovative Spine surgery products. The agreement covers the distribution of its DenerveX™ System throughout Israel. Dennis Moon, Medovex Executive Vice President, stated, "M.Fast Technologies LTD serves as a perfect call point fit for our mission to provide a..."/>
Medovex Corporation Enters Into International Distribution Agreement With M.Fast Technologies LTD
Biostage, Inc.,, a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus and trachea, today announced that it will be presenting at the 2016 Aegis Growth Conference being held September 20-22, 2016 at the Encore at Wynn Las Vegas in Las Vegas, NV. Jim McGorry, CEO of Biostage will present on Wednesday, September 21, 2016 at 11:30 p.m. PT."/>
Biostage to Present at the 2016 Aegis Growth Conference
Novocure’ s broadly applicable mechanism of action. HELIER, Jersey---- Novocure announced today that two independent institutions published scientific research on Tumor Treating Fields, representing increasing external interest from the scientific community in Novocure’ s innovative, proprietary therapy. The published data support Novocure’ s existing body of research establishing TTFields as a..."/>
Two Institutions Publish Independent Data on Novocure’s Tumor Treating Fields
InVivo Therapeutics Holdings Corp. today announced that Nicholas Theodore, M.D., Director of the John Hopkins Neurosurgical Spine Center, will be giving an oral platform presentation titled“ High AIS Grade Conversion Rate Following Neuro-Spinal Scaffold Implantation in Acute Thoracic Complete AIS A Spinal Cord Injury: Potential Mechanisms” at the 2016 Congress of Neurological Surgeons Annual Meeting to be held September 24-28, 2016 in San Diego, CA."/>
InVivo Therapeutics Announces Oral Platform Presentation at 2016 Congress of Neurological Surgeons Annual Meeting

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology698 Articles
Consumer Discretionary593 Articles
Financials457 Articles
Industrials386 Articles
Health Care384 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at